|Synonyms||Doxyfluridine; 5'-Deoxy-5-fluorouridine; 5'-Fluoro-5'-deoxyuridine; 5'-dFUrd; 5'-DFUR|
|Chemical and physical data|
|Molar mass||246.19 g·mol−1|
|3D model (JSmol)|
Doxifluridine is a second generation nucleoside analog prodrug developed by Roche and used as a cytostatic agent in chemotherapy in several Asian countries including China and South Korea. Doxifluridine is not FDA-approved for use in the USA. It is currently being evaluated in several clinical trials as a stand alone or combination therapy treatment.
5'-deoxy-5'-fluorouridine, 5'-deoxy-5-fluorouridine, 5'-DFUR, 5'-fluoro-5'-deoxyuridine, doxifluridine, doxyfluridine, Furtulon, Ro 21-9738
5-fluorouracil (5-FU) is currently an FDA-approved antimetabolite. 5-FU is normally administered intravenously to prevent its degradation by dihydropyrimidine dehydrogenase in the gut wall. Doxifluridine (5´-deoxy-5-fluorouridine) is a fluoropyrimidine derivative of 5-FU, thus a second-generation nucleoside prodrug. Doxifluridine was designed to improve oral bioavailability in order to avoid dihydropyrimidine dehydrogenase degradation in the digestive system.
Within a cell, pyrimidine nucleoside phosphorylase or thymidine phosphorylase can metabolize doxifluridine into 5-FU. It is also a metabolite of capecitabine. High levels of pyrimidine-nucleoside phosphorylase and thymidine phosphorylase are expressed in esophageal, breast, cervical, pancreatic, and hepatic cancers. Liberation of 5-FU is the active metabolite and leads to inhibition of DNA synthesis and cell death.
High thymidine phosphorylase expression is also found in the human intestinal tract, resulting in dose-limiting toxicity (diarrhea) in some individuals.
The most frequent adverse effects for doxifluridine were neurotoxicity and mucositis.
Ai Feng - Hengrui, China; Didox - Shin Poong, South Korea; Doxifluridine-XinShiDai Pharm - XinShiDai Pharmaceutical, China; Doxyfluridine Kwangdong - Kwang Dong, South Korea; Furtulon - Roche, China; Ke Fu - Zhaohui, China; Ke Tuo - Southwest, China; Qi Nuo Bi Tong - Wanjie High-Tech, China; Shu Qi - Team, China; Tan Nuo- Xinchang Medicine & Chemical Co Ltd, China; Yi Di An - Pacific, China; Doxifluridine cap- Myungmoon Pharma Co. Ltd.
- "Doxifluridine". drugs.com.
- Shelton J, Lu X, Hollenbaugh JA, Cho JH, Amblard F, Schinazi RF (Dec 2016). "Metabolism, Biochemical Actions, and Chemical Synthesis of Anticancer Nucleosides, Nucleotides, and Base Analogs". Chem Rev. 116 (23): 14379–14455. doi:10.1021/acs.chemrev.6b00209. PMID 27960273.
- Schöffski P (Feb 2004). "The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors". Anticancer Drugs. 15 (2): 85–106. PMID 15075664.
- Ishikawa, T; Sekiguchi, F; Fukase, Y; Sawada, N; Ishitsuka, H (1998). "Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts". Cancer Research. 58 (4): 685–90. PMID 9485021.
- "Definition of Doxifluridine". NCI Drug Dictionary. National Cancer Institute.
- Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, Nagasue N, Yamana H, Hirakawa-YS Chung K, Ikeda T, Takasaki K, Oka M, Kameyama M, Toi M, Fujii H, Kitamura M, Murai M, Sasaki H, Ozono S, Makuuchi H, Shimada Y, Onishi Y, Aoyagi S, Mizutani K, Ogawa M, Nakao A, Kinoshita H, Tono T, Imamoto H, Nakashima Y, Manabe T (Jul 2000). "Expression levels of thymidine phosphorylase and dihyropyrimidine dehydrogenase in various human tumor tissues". Int J Oncol. 17 (1): 33–8. PMID 10853015.
- Ogata Y, Sasatomi T, Mori S, Matono K, Ishibashi N, Akagi Y, Fukushima T, Murakami H, Ushijima M, Shirouzu K (Jul 2007). "Significance of thymidine phosphorylase in metronomic chemotherapy using CPT-11 and doxifluridine for advanced colorectal carcinoma". Anticancer Res. 27 (4C): 2605–11. PMID 17695422.
- Lamont EB, Schilsky RL (Sep 1999). "The oral fluoropyrimidies in cancer chemotherapy". Clin Cancer Res. 5 (9): 2289–96. PMID 10499595.